Latest medical treatment strategies for venous thromboembolism.
Anticoagulant therapy with unfractionated heparin (UFH) followed by warfarin prevents thrombus extension, reduces the risk of recurrent thrombosis and prevents death in patients with venous thromboembolism (VTE). Low-molecular-weight heparin (LMWH) has replaced UFH as the preferred initial anticoagulant therapy for VTE because it is as effective and safe as UFH, but does not require laboratory monitoring and is less likely to cause immune thrombocytopenia and osteoporosis. More recently, fondaparinux has been shown to be an effective and safe alternative to LMWH and several new parenteral anticoagulants are being evaluated. The most important unmet need in the anticoagulant management of VTE is a replacement for warfarin. New oral anticoagulants that selectively target individual steps in the coagulation cascade have been shown to be effective for the long-term treatment of VTE in Phase II and III trials and are likely to become available in the near future.
McRae
Simon J
SJ
The Queen Elizabeth Hospital, Institute of Medical and Veterinary Sciences, Department of Haematology-Oncology, 28 Woodville Rd, Woodville 5011, Adelaide, South Australia, Australia. Simon.Mcrae@imvssa.gov.au
Eikelboom
John W
JW
D000925:Anticoagulants / Q000627:therapeutic use; D001777:Blood Coagulation; D006801:Humans; D013923:Thromboembolism / Q000188:drug therapy* / Q000503:physiopathology; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000503:physiopathology
D000925:Anticoagulants